The Angelini family, an Italian pharmaceutical dynasty with an estimated net worth of $10 billion, has significantly expanded its global reach by acquiring the U.S.-based rare disease biotech Catalyst Pharmaceuticals for $4.1 billion. This strategic move, led by fourth-generation shareholder Thea Paola Angelini and CEO Sergio Marullo di Condojanni, marks a departure from the family's traditional European focus. The acquisition aims to rekindle innovation within Angelini Pharma and includes the establishment of a $350 million venture fund to invest in life sciences startups. AI
RANK_REASON Major acquisition by a large, established family business into a new market. [lever_c_demoted from significant: ic=1 ai=0.0]
- Angelini family
- Angelini Industries
- Angelini Pharma
- Blackstone
- Catalyst Pharmaceuticals
- CDP Equity
- Francesco Angelini
- Nouscom
- Rich Daly
- Sergio Marullo di Condojanni
- Thea Paola Angelini
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
